Matinas BioPharma Holdings Inc (MTNB) Releases Quarterly Earnings Results, Misses Expectations By $0.21 EPS

Matinas BioPharma Holdings Inc (NASDAQ:MTNB) posted its quarterly earnings results on Tuesday, May 16th. The company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.21, Bloomberg Earnings reports. The company had revenue of $0.02 million during the quarter.

Matinas BioPharma Holdings (MTNB) traded up 4.40% during trading on Friday, reaching $2.85. The company had a trading volume of 3,374,290 shares. The firm’s market capitalization is $260.48 million. The company’s 50-day moving average is $2.71 and its 200 day moving average is $2.53. Matinas BioPharma Holdings has a 52 week low of $0.58 and a 52 week high of $3.99.

An institutional investor recently bought a new position in Matinas BioPharma Holdings stock. Goldman Sachs Group Inc. bought a new stake in shares of Matinas BioPharma Holdings Inc (NASDAQ:MTNB) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 221,706 shares of the company’s stock, valued at approximately $614,000. Goldman Sachs Group Inc. owned about 0.25% of Matinas BioPharma Holdings as of its most recent filing with the SEC.

WARNING: “Matinas BioPharma Holdings Inc (MTNB) Releases Quarterly Earnings Results, Misses Expectations By $0.21 EPS” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/06/16/matinas-biopharma-holdings-inc-mtnb-announces-quarterly-earnings-results-updated-updated-updated.html.

A number of research analysts recently commented on the company. Aegis reissued a “positive” rating and issued a $8.00 price target on shares of Matinas BioPharma Holdings in a report on Tuesday, March 28th. Maxim Group set a $6.00 price objective on Matinas BioPharma Holdings and gave the stock a “buy” rating in a research note on Thursday, March 2nd.

Matinas BioPharma Holdings Company Profile

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply